)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Cadrenal Therapeutics
Cadrenal Therapeutics (CVKD) investor relations material
Cadrenal Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary31 Mar, 2026
Executive summary
Reported encouraging Phase 2 results for CAD-1005 in HIT, showing a significant reduction in thrombotic events versus placebo on top of standard anticoagulant therapy.
Completed End-of-Phase 2 FDA meeting, clarifying the regulatory path for a planned Phase 3 pivotal trial of CAD-1005.
CAD-1005 remains the near-term development priority, with broader 12-LOX platform opportunities under evaluation.
Financial highlights
Research and development expenses for Q4 2025 were $0.7 million, down from $1.5 million in Q4 2024.
General and administrative expenses for Q4 2025 were $2.4 million, compared to $2.7 million in Q4 2024.
Net loss for Q4 2025 was $3.0 million, improved from $4.2 million in Q4 2024.
Cash and cash equivalents as of December 31, 2025, totaled $4.0 million.
Outlook and guidance
Incorporating FDA feedback into the Phase 3 protocol for CAD-1005 is underway.
Evaluating financing and strategic alternatives to support planned clinical development activities.
Continuing to assess longer-term opportunities for the 12-LOX platform in indications beyond HIT.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cadrenal Therapeutics
- CAD-1005 moves to phase III for HIT, aiming to address a critical unmet need with strong safety data.CVKD
Life Sciences Virtual Investor Forum12 Mar 2026 - Tecarfarin targets unmet anticoagulation needs in LVAD patients, with pivotal trials and partnerships ahead.CVKDSidoti Micro-Cap Virtual Conference2 Feb 2026
- Tecarfen aims to replace warfarin for high-risk heart patients, nearing FDA review with strong data.CVKDSummer 2024 Investor Summit Virtual MicroCap Forum23 Jan 2026
- Tecarfarin aims to displace warfarin, with pivotal LVAD studies and strong regulatory momentum.CVKDLytham Partners Fall 2024 Investor Conference19 Jan 2026
- VLX-1005 and Tecarfarin lead a strategy to address unmet needs in rare anticoagulation markets.CVKD2nd Annual Lytham Partners Healthcare Investor Summit15 Jan 2026
- VLX-1005 leads a pipeline targeting critical gaps in anticoagulation for rare, high-risk patients.CVKDInvestor presentation15 Jan 2026
- Tecarfarin targets gaps in anticoagulation for rare heart conditions; a pivotal trial is planned for 2025.CVKDLytham Partners 2025 Investor Healthcare Summit10 Jan 2026
- Registers 428,227 shares for resale from warrant exercises, with proceeds for working capital.CVKDRegistration Filing29 Dec 2025
- Registering 590,001 shares for resale, proceeds from warrant exercises will fund Phase 3 trial.CVKDRegistration Filing16 Dec 2025
Next Cadrenal Therapeutics earnings date
Q1 20267 May, 2026
Cadrenal Therapeutics
Next Cadrenal Therapeutics earnings date
Q1 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage